Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KATHERINE B REED

Allopathic & Osteopathic Physicians Dermatology

NPI
1396919569
CMS profile
335358
Location
SPOKANE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$547.33

32 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $547.33 32

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KATHERINE B REED

NPI 1396919569 · CMS profile ID 335358

Allopathic & Osteopathic Physicians / Dermatology

SPOKANE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1396919569?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KATHERINE B REED, NPI 1396919569, CMS profile ID 335358. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1396919569?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). KATHERINE B REED, NPI 1396919569, CMS profile ID 335358. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1396919569?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
KATHERINE B REED, NPI 1396919569, CMS profile ID 335358, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1396919569?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

32 matching records · $547.33 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 32 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–32 of 32.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $15.0711/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694219337 CMS
Lilly USA, LLC $17.4011/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657930113 CMS
Novartis Pharmaceuticals Corporation $13.0710/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659860567 CMS
Biofrontera Inc. $7.7710/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 690544023 CMS
AbbVie, Inc. $18.9710/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699319 CMS
Celgene Corporation $23.9408/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672886457 CMS
Amgen Inc. $12.1208/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662591459 CMS
Novartis Pharmaceuticals Corporation $17.5708/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659860565 CMS
Lilly USA, LLC $15.8708/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657943901 CMS
AbbVie, Inc. $21.3407/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699313 CMS
Celgene Corporation $24.3607/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672886273 CMS
GENZYME CORPORATION $17.8707/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694098869 CMS
Lilly USA, LLC $18.1207/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657950651 CMS
PFIZER INC. $16.4606/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672253685 CMS
AbbVie, Inc. $17.9206/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699331 CMS
Integra LifeSciences Corporation $25.3306/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697158539 CMS
AbbVie, Inc. $15.5206/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699327 CMS
AbbVie, Inc. $17.0105/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699311 CMS
Novartis Pharmaceuticals Corporation $12.2505/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659860563 CMS
PruGen, Inc. Pharmaceuticals $13.5605/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 707764987 CMS
PFIZER INC. $18.4505/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672021947 CMS
Lilly USA, LLC $14.2405/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657930111 CMS
AbbVie, Inc. $17.1304/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699353 CMS
Amgen Inc. $13.2104/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662591457 CMS
Helsinn Therapeutics (U.S.), Inc. $15.7804/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655947391 CMS
AbbVie, Inc. $15.0403/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699325 CMS
Lilly USA, LLC $17.2003/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657950649 CMS
PFIZER INC. $20.0902/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671891609 CMS
Biofrontera Inc. $20.9702/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 667996653 CMS
PFIZER INC. $16.6502/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671853273 CMS
Lilly USA, LLC $19.9101/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657926571 CMS
AbbVie, Inc. $17.1401/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699321 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $547.33 32
PY2020 $413.54 18
PY2021 $570.86 34
PY2022 $538.17 34
PY2023 $498.08 30
PY2024 $705.53 35
PY2025 $1,169.72 67

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $734,267.33 246
PY2024 Principal investigator $853,745.12 356
PY2023 Principal investigator $644,757.85 253
PY2022 Principal investigator $361,336.03 142
PY2021 Principal investigator $277,998.71 117
PY2020 Principal investigator $149,365.00 24
PY2019 Principal investigator $53,682.69 24

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

117 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $138.30 12/28/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903871
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $98.92 12/28/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903873
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $39.38 12/28/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903875
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $562.72 12/28/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903877
Principal investigator 1 Incyte Corporation $14,188.58 12/23/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Mechanism of Action of Ruxolitinib Cream for Vitiligo No dispute reported 06/30/2026 831141889
Principal investigator 1 Incyte Corporation $7,572.99 12/23/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 831141891
Principal investigator 1 Incyte Corporation $2,955.37 12/23/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831141893
Principal investigator 1 Incyte Corporation $3,906.05 12/23/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831141895
Principal investigator 1 Incyte Corporation $1,098.00 12/17/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831141887
Principal investigator 1 ABBVIE INC. $1,250.00 12/02/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 792485361
Principal investigator 1 ABBVIE INC. $1,366.75 12/02/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 792485363
Principal investigator 1 Incyte Corporation $1,863.00 11/26/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831141877
Principal investigator 1 Incyte Corporation $14,440.26 11/26/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831141881
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $12,585.37 11/23/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903887
Principal investigator 1 ABBVIE INC. $1,395.25 11/10/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 792482613
Principal investigator 1 Incyte Corporation $2,000.00 11/05/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 831141879
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $382.80 11/04/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903865
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $179.44 11/04/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903867
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $89.72 11/04/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903869
Principal investigator 1 Incyte Corporation $1,566.00 10/29/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831141875
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $33.27 10/26/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903885
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $8,786.25 10/21/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903883
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $81.60 10/20/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903861
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $17.64 10/20/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903863
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $32.50 10/14/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903859
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $967.20 10/07/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903881
Principal investigator 1 ABBVIE INC. $1,147.75 10/06/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 792477765
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $5,871.37 10/05/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903879
Principal investigator 1 Incyte Corporation $3,323.25 10/01/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831141873
Principal investigator 1 ABBVIE INC. $8,000.00 09/21/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792475981
Principal investigator 1 ABBVIE INC. $1,062.75 08/31/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 792473649
Principal investigator 1 Incyte Corporation $1,566.00 08/27/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831141859
Principal investigator 1 Incyte Corporation $1,037.25 08/27/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831141863
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $6,905.25 08/19/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903855
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $250.88 08/04/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903847
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $89.72 08/04/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903849
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $701.80 08/04/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903851
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $24.69 08/04/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903853
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $89.72 08/04/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903903
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $89.72 08/04/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903905
Principal investigator 1 Incyte Corporation $1,029.50 08/03/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831141861
Principal investigator 1 Incyte Corporation $7,155.00 07/30/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 831141847
Principal investigator 1 Incyte Corporation $3,514.50 07/30/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831141849
Principal investigator 1 ABBVIE INC. $1,240.25 07/29/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 792470737
Principal investigator 1 ABBVIE INC. $2,200.00 07/22/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 792468485
Principal investigator 1 ABBVIE INC. $8,400.00 07/21/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 792468289
Principal investigator 1 ABBVIE INC. $1,147.75 07/14/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 792467665
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $15,174.00 07/13/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903857
Principal investigator 1 Incyte Corporation $6,609.30 06/25/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Mechanism of Action of Ruxolitinib Cream for Vitiligo No dispute reported 06/30/2026 831141851
Principal investigator 1 Incyte Corporation $1,370.25 06/25/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831141853
Principal investigator 1 Incyte Corporation $1,677.37 06/25/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831141855
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $32.50 06/17/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903823
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $6,674.62 06/10/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903837
Principal investigator 1 ABBVIE INC. $2,758.15 06/02/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 792461813
Principal investigator 1 Incyte Corporation $620.00 06/01/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 831141733
Principal investigator 1 Incyte Corporation $1,000.00 06/01/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 831141739
Principal investigator 1 Incyte Corporation $335.00 06/01/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 831141745
Principal investigator 1 Incyte Corporation $4,351.50 05/28/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831141781
Principal investigator 1 Incyte Corporation $3,124.56 05/28/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831141787
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $38.40 05/26/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903845
Principal investigator 1 ABBVIE INC. $304.00 05/10/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 792456289
Principal investigator 1 Incyte Corporation $75.00 05/04/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 831141703
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $263.20 05/04/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903831
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $765.60 05/04/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903833
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $255.20 05/04/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903835
Principal investigator 1 Incyte Corporation $3,818.25 04/30/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831141821
Principal investigator 1 Incyte Corporation $2,626.88 04/30/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831141827
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $11.00 04/23/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903827
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $44.10 04/23/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903829
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $38.40 04/22/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903825
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $16,908.75 04/22/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903841
Principal investigator 1 ABBVIE INC. $5,027.40 04/09/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 792444391
Principal investigator 1 ABBVIE INC. $1,028.00 04/08/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792443273
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $32.00 04/02/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903843
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $5,000.00 04/01/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903839
Principal investigator 1 Incyte Corporation $5,409.00 03/26/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831141763
Principal investigator 1 Incyte Corporation $2,758.50 03/26/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831141769
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $32.00 03/23/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903819
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $20,918.25 03/23/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903821
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $19.00 03/19/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903795
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $313.60 03/19/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903801
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $224.30 03/19/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903803
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $107.16 03/19/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903805
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $44.86 03/19/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903809
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $89.72 03/19/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903811
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $382.80 03/19/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903813
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $49.38 03/19/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903815
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $88.20 03/19/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903817
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $38.08 03/18/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903799
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $255.20 03/18/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903807
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $27.00 03/05/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903797
Principal investigator 1 ABBVIE INC. $15,899.05 03/02/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 792430619
Principal investigator 1 Incyte Corporation $5,042.25 02/26/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831141751
Principal investigator 1 Incyte Corporation $3,839.63 02/26/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831141757
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $32.50 02/16/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903789
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $38.40 02/05/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903791
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $22.80 02/04/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903775
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $22.00 02/04/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903777
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $376.32 02/04/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903779
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $269.16 02/04/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903781
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $107.16 02/04/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903783
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $197.40 02/04/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903785
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $59.04 02/04/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903787
Principal investigator 1 Incyte Corporation $1,737.00 01/29/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831141833
Principal investigator 1 Incyte Corporation $2,758.50 01/29/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831141839
Principal investigator 1 ABBVIE INC. $1,913.45 01/28/2021 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 792417187
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $102.00 01/15/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903773
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $575.00 01/15/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903793
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $22.00 01/14/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903761
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $125.44 01/14/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903763
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $89.72 01/14/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903765
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $526.40 01/14/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903767
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $510.40 01/14/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903769
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $59.04 01/14/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903771
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $89.72 01/14/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903899
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $89.72 01/14/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903901
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $329.62 01/01/2021 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 852903759